Related to A Clearer Regulatory Pathway for Cell Therapy May Help Improve Investment

• Pfizer Inks Stem Cell Development Agreement with University College London
  
• NeoStem Obtains Stem Cell Technology for Chronic Wound Healing
  
• Geron’s hESC Therapy for Spinal Cord Injury Has Been Placed on Hold
  
• BrainStorm Cell Therapeutics Taps Israeli CMO for Stem Cell Production
  
• BioTime Sets Up Subsidiary in China to Develop Stem Cell Therapeutics
  
• Russian Stem Cell Company Hopes to Raise Roughly $5.54M through IPO on Moscow Stock Exchange
  
• BioTime Sets Up Subsidiary to Develop hESC-Based Therapies for Cancer
  
• Cellerix to Test Gamida’s Expansion Technologies with Its Stem Cell-Based Drugs
  
• Intercytex Wind-Down Continues with Sale of Stem Cell Therapies Assets to Pfizer for $750,000
  
• Geron to Study Its hESC Product in Alzheimer Disease with University of California
  
• Schepens Eye Institute Receives Unrestricted Grant to Progress Retinal Stem Cell Collaboration with ReNeuron
  
• ReNeuron Raises £4.7M to Fund Phase I Study with Stem Cell Therapy for Ischemic Stroke
  
• Benefits of Osiris’ Mesenchymal Stem Cell Therapy Confirmed in Late-Stage Studies against SR-GvHD
  
• T2cure’s Mid-Stage Somatic Stem Cell Product Receives EMEA Quality Certification
  
• BioTime Sets Up OrthoCyte Subsidiary for Stem Cell Based Orthopedic Products
  
• CIRM Commits $25M to Overcome Immune Rejection of Stem Cell Therapies
  
• FDA Clears Geron to Start World’s First Trial with hESC Therapy
  
• Scientists Develop Dissolving Adjuvant Backpacks for Cell Therapy
  
• California Institute for Regenerative Medicine Bankrolls 12 Grants with $243M
  
• URMC Gets $15M to Study Homspera as a Radiation-Induced Injury Countermeasure